MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS), a leading biopharmaceutical company, announced this week the filing of a patent application that covers the use of buntanetap and its analogues for the treatment of neuropsychiatric conditions. The move comes on the heels of the U.S. Provisional Application No. 63/440,890 filed in January 2023.
The patent application, titled “Treatment of Mental Illness via Administration of Buntanetap and Analogues Thereof,” details methods for treating, inhibiting, or slowing the onset of mental illnesses using buntanetap or its pharmaceutically acceptable salts. Buntanetap can be used independently or synergistically with effective quantities of antipsychotic agents, antidepressant agents, hallucinogenic agents, or a combination thereof.
The application targets mental illnesses such as autism, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, anxiety, and schizophrenia. These conditions have been shown to share similar pathological abnormalities with certain neurodegenerative diseases, including disruptions in the synthesis of neurotoxic proteins, impairment of axonal transport, inflammation, and nerve cell death.
Through its ability to target these mechanisms, buntanetap has demonstrated statistically significant improvements in obsessive-compulsive behavior, anxiety, and fear in preclinical studies conducted on mice.
“The ability of buntanetap to inhibit a wide range of neurotoxic proteins, as shown in our Alzheimer’s and Parkinson’s studies, is associated with improved mental health which opens new avenues for delaying or treating certain mental conditions,” said Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio.
The filing of this patent application significantly bolsters Annovis Bio’s already robust intellectual property portfolio. Notably, this expansion incorporates mental illness alongside its existing focus on neurodegenerative diseases. By protecting its innovative discoveries in both areas, Annovis Bio is poised to make even greater strides in advancing treatments and improving lives.
Annovis Bio’s current patents and patent applications cover the use of buntanetap for chronic and acute neurodegenerative diseases, its mechanism of action, and a novel composition of matter for a polymorph of buntanetap. The latest filing signals a significant step forward in the ongoing quest for innovative treatments for mental health disorders.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.